Tue, Jan 27, 2015, 3:22 PM EST - U.S. Markets close in 38 mins.


% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

  • left2rightdoor left2rightdoor Dec 27, 2012 10:49 PM Flag

    Got more shares today

    Below $3 is a good entry or addition point
    Military;s Dengue Vaccine 0 story June 2012 US Medicine
    This vaccine candidate, the culmination of 19 years of work, is the first tetravalent dengue DNA vaccine to undergo human testing. Partnering with Vical, a San Diego-based biopharmaceutical research enterprise. NMRC researchers developed the tetravalent DNA vaccine formulated with Vical’s Vaxfectin adjuvant. The Phase 1 human clinical trial that began this year is evaluating the vaccine formulated with and without Vaxfectin.

    “We partnered with Vical to use their adjuvant to enhance the immune response,” Capt. Kevin Porter, director of infectious diseases research at the Naval Medical Research Center, told U.S. Medicine.

1.035-0.045(-4.17%)3:20 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.